Prism Medico & Pharmacy Ltd
₹ 29.0
-3.33%
01 Jun
- close price
About
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products[1]
Key Points
- Market Cap ₹ 39.3 Cr.
- Current Price ₹ 29.0
- High / Low ₹ 34.5 / 12.5
- Stock P/E 123
- Book Value ₹ 25.4
- Dividend Yield 0.00 %
- ROCE 2.82 %
- ROE 2.10 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.14 times its book value
Cons
- Promoter holding is low: 30.2%
- Company has a low return on equity of 0.55% over last 3 years.
- Company has high debtors of 588 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.09 | 0.09 | 20.96 | 36.31 | 26.89 | 16.76 | 8.44 | 1.27 | 2.93 | 0.63 | 2.44 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| 0.06 | 0.15 | 0.37 | 20.86 | 35.98 | 26.94 | 16.92 | 8.93 | 1.37 | 3.06 | 0.71 | 2.04 | |
| Financing Profit | -0.06 | -0.06 | -0.28 | 0.10 | 0.33 | -0.05 | -0.16 | -0.49 | -0.10 | -0.14 | -0.08 | 0.40 |
| Financing Margin % | -66.67% | -311.11% | 0.48% | 0.91% | -0.19% | -0.95% | -5.81% | -7.87% | -4.78% | -12.70% | 16.39% | |
| 0.06 | 0.06 | 0.07 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | 0.03 | |
| Depreciation | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -0.01 | -0.01 | -0.23 | 0.05 | 0.29 | -0.07 | -0.17 | -0.50 | -0.11 | -0.03 | -0.06 | 0.43 |
| Tax % | 0.00% | 0.00% | 0.00% | 140.00% | -24.14% | -28.57% | -29.41% | -26.00% | -27.27% | -33.33% | -33.33% | 25.58% |
| -0.01 | -0.01 | -0.23 | -0.02 | 0.37 | -0.05 | -0.13 | -0.37 | -0.08 | -0.02 | -0.05 | 0.32 | |
| EPS in Rs | -0.05 | -0.05 | -0.38 | -0.03 | 0.61 | -0.08 | -0.21 | -0.61 | -0.13 | -0.03 | -0.08 | 0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 39% |
| 5 Years: | -32% |
| 3 Years: | 24% |
| TTM: | 287% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 35% |
| 3 Years: | 82% |
| TTM: | 740% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | -1% |
| 1 Year: | 83% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 1.99 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | -0.36 | -0.36 | 6.74 | 6.72 | 7.09 | 6.99 | 6.86 | 6.49 | 9.10 | 9.08 | 9.03 | 9.35 |
| Borrowing | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.04 | 0.16 | 0.25 | 0.16 | 3.82 | 8.54 | 8.63 | 0.02 | 0.23 | 0.10 | 0.47 | 0.20 | |
| Total Liabilities | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 | 15.61 |
| 0.01 | 0.00 | 0.16 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 10.00 | 11.25 | 10.00 | 1.94 | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.68 | 1.86 | 2.89 | 1.58 | 6.88 | 19.58 | 19.55 | 12.52 | 15.36 | 15.21 | 15.53 | 15.58 | |
| Total Assets | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 | 15.61 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.05 | -0.82 | -0.06 | -1.23 | -4.36 | -0.05 | -2.38 | 2.95 | -0.01 | -0.02 | 0.00 | |
| 0.00 | 0.46 | 0.30 | -1.25 | 1.25 | 4.36 | 0.02 | 2.35 | -2.91 | 0.00 | 0.00 | 0.00 | |
| 0.02 | 0.05 | 1.33 | -0.05 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | |
| Net Cash Flow | 0.02 | 0.56 | 0.81 | -1.36 | 0.08 | -0.01 | -0.03 | -0.03 | 0.04 | -0.01 | -0.02 | 0.00 |
| Free Cash Flow | 0.01 | 0.05 | -0.99 | -0.06 | -1.23 | -4.36 | -0.05 | -2.38 | 2.95 | -0.01 | -0.02 | 0.00 |
| CFO/OP | -17% | -83% | 293% | -50% | -355% | 8,660% | 31% | 486% | -3,220% | 8% | 25% | 0% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -0.61% | -0.61% | -3.19% | -0.16% | 4.24% | -0.38% | -1.00% | -2.91% | -0.58% | -0.13% | -0.33% | 2.10% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings INR |
|
|||||||||||
| Revenue from Agriculture Products INR Lacs |
||||||||||||
| Key Management Personnel (KMPs) count |
||||||||||||
| Trade Receivables Turnover ratio |
||||||||||||
| Purchase of Stock-in-Trade (Medical Devices) INR |
||||||||||||
| Revenue from Bathroom Fittings (Subsidiary) INR Lacs |
||||||||||||
| Revenue from Cattle Feed (Subsidiary) INR Lacs |
||||||||||||
| Sales to Related Party (Galaxy Pharma Kenya) INR Lacs |
||||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
28 May - Board approved audited standalone results for FY ended 31 March 2026; auditors issued unmodified opinion.
-
Board Meeting Intimation for Regulation 29(1) Of SEBI (LODR) Regulations, 2015.
23 May - Board meeting on 28 May 2026 to approve audited standalone results for year ended 31 March 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting - Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
11 May - Board on 11 May 2026 appointed Harpreet Singh, S Harpreet and Associates, as internal auditor for FY2025-26.
-
Announcement under Regulation 30 (LODR)-Allotment
5 May - Board approved allotment of 75 lakh shares and 50 lakh convertible warrants on May 5, 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting For Allotment Of Securities
5 May - Board approved allotment of 75 lakh shares and 50 lakh warrants on preferential basis on May 5, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
PMPL deals in chemicals, serums, chemical products, antibiotics, medicines, drugs,
pharmaceuticals, pesticides, dyes, soaps, oils, perfumes, cosmetics, patent medicines, etc.